Faculty & Staff Details

	Name:	Sanjay K. Srivastava
	Position:	Professor
	Email:	sanjay.srivastava@ttuhsc.edu
	Bio	Dr. Sanjay K. Srivastava is a Professor of Biomedical Sciences specializing in cancer biology. He joined the TTUHSC School of Pharmacy as an Associate Professor in 2007. Prior to his arrival at TTUHSC, Dr. Srivastava served from 2000-2007 as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute. He also served as Research Scientist at Mercy Cancer Institute, Mercy Hospital, Pittsburgh from 1995-2000 and did his post-doc from University of Texas Medical Branch at Galveston, Texas from 1992-1995. Dr. Srivastava received a B.S. in Physics, Chemistry & Math and a M.S. in Biochemistry from Lucknow University, India. His Ph.D. is in Biochemistry and Toxicology from Industrial Toxicology Research Center, Lucknow and Kanpur University, Kanpur, India. His research interests include cancer biology, chemoprevention of cancers by phytochemicals, chemical carcinogenesis and cell signaling. Dr. Srivastava is currently funded by the National Cancer Institute, NIH. He has authored over 100 research papers and is a member of the American Association for Cancer Research, Society of Toxicology and AAPS. Dr. Srivastava is in the editorial board of several journals and ad-hoc reviewer of numerous scientific journals and also member of the study section of the National Institute of Health (NIH), Department of Defense and Susan G. Komen Breast Cancer Foundation. His research work has been featured by news agencies including BBC, MSNBC, CBS, ABC, Science News etc. and can be obtained from the following: BBC News_Pancreatic Cancer

Education:

Mini-MBA. Business Essentials for Bioscientists, University of Pittsburgh, USA (Katz Graduate School of Business), 2002
Ph.D. Biochemical Toxicology, ITRC/Kanpur University, India, 1991
M. S. Biochemistry, Lucknow University, India, 1987
B. S. Physics, Chemistry, Mathematics, Lucknow University, India, 1985

Research Interests:

Dr. Srivastava’s laboratory is interested in understanding the molecular mechanisms of chemotherapeutic agents of natural origin against pancreatic, ovarian, and breast cancers. His group is studying the modulation of key signal transduction pathways that are deregulated in cancer cells by agents such as benzyl isothiocyanate, phenethyl isothiocyanate, capsaicin, diindolylmethane, triphala, panabinostat, curcubitacin B and deguelin at both cellular and in vivo model. In addition, his group is interested in environmental carcinogen-induced cell signaling pathways, DNA-adduct formation and chemical carcinogenesis. Currently, his research is funded by National Cancer Institute, NIH.

The long-term goals of Dr. Srivastava’s research program are to:
• Identify novel dietary or synthetic chemopreventive agents
• Understand their mechanism of action at the cellular and molecular level
• Explore their efficacy in vivo in preclinical experiments with suitable animal models and to verify changes in surrogate biomarkers
• Investigate the synergistic effects of dietary agents with chemotherapeutic agents against cancer cells
• Use the information obtained in preclinical studies to design and conduct phase I clinical trials
• Establish pharmacokinetic data for the anticancer agents in humans, which will help to optimize further phase II/III chemoprevention trials

Publications:

RECENT PUBLICATIONS (Author of more than 100 publications):

1. P. K. Kandala and Sanjay K. Srivastava (2012). Diindolylmethane mediated Gli1 suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation in vivo. J. Biol. Chem. 287, 28745-28754.
2. K.C. Pramanik and Sanjay K. Srivastava (2012). ASK1-Trx complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis. Antioxid. Redox Signal. Epub. June 11, 2012.
3. S.R. Boreddy and Sanjay K. Srivastava (2012). Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial to mesenchymal transition (EMT) in an orthotopic model. Oncogene (In Press). NIHMS396872.
4. P. Gupta and Sanjay K. Srivastava (2012). Anti-tumor activity of phenethyl isothiocyanate in HER2 positive breast cancer models BMC-Medicine 10:80, 1-18.
5. P. K. Kandala and Sanjay K. Srivastava (2012). Diindolylmethane induces ER stress mediated autophagy in ovarian cancer cells. Oncotarget , 3(4), 435-449.
6. P. Kandala and Sanjay K. Srivastava (2012). Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting STAT-3. BMC-Medicine, 10(1):9, 1-18.
7. P. Kandala, S.W. Wright and Sanjay K. Srivastava (2012). Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J. Pharmacol. Exp. Therap., 341, 24-32.
8. S. Loganathan, P.K. Kandala, P. Gupta and Sanjay K. Srivastava (2012). Inhibition of EGFR-Akt axis results in the suppression of ovarian tumors in vitro and in a preclinical mouse model. PLoS ONE, 7 (8), e43577, 1-11.
9. P. K. Kandala and Sanjay K. Srivastava (2012). Janus Activated Kinase 2 is a target of diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discoveries and Therapeutics, 6(2), 94-101.
10. P. Gupta, C.A. Adkins, P.L. Lockman and Sanjay K. Srivastava (2012). Anti-metastatic effects of phenethyl isothiocyanate in a novel mouse model of breast tumor metastasis to brain. (Under Review).
11. K.C. Pramanik and Sanjay K. Srivastava (2012). CBP mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT. (Under Review).
12. N.M. Fofaria and Sanjay K. Srivastava (2012). Activation of ATR/Chk1 by piperine causes cell cycle arrest and apoptosis in melanoma cells. (Under Review).
13. K.C. Pramanik, S.K. Kudugunti, M.Y. Moridani and Sanjay K. Srivastava (2012). Caffeic acid phenethyl ester suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway. (Under Review).
14. S.R. Boreddy, K.C. Pramanik and Sanjay K. Srivastava (2011). Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/Akt/FOXO pathway. Clinical Cancer Research, 17, 1784-1795. (Work featured on the cover page of the journal).
15. K.C. Pramanik, S.R. Boreddy and Sanjay K. Srivastava (2011). Involvement of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress lead to apoptosis in pancreatic cancer cells. PLoS ONE. 6 (5), e20151, 1-16.
16. R. Sahu, S. Batra, P. Kandala, T.L. Brown and Sanjay K. Srivastava (2011). Mutation in the K-Ras gene is associated with resistance to TRAIL-induced apoptosis in pancreatic and lung cancer cells. Cancer Chemotherapy and Pharmacology, Published Online 17 September, 2010; 67, 481-487.
17. S.R. Boreddy, R.P. Sahu and Sanjay K. Srivastava (2011). Benzyl isothiocyanate suppress pancreatic tumor angiogenesis and invasion by inhibiting HIF-1a/VEGFR/Rho-GTPases. Pivotal role of STAT-3. PLoS ONE, 6 (10), e25799, 1-12.
18. Bai H, Li H, Zhang W, Matkowskyj, Liao J, Sanjay K. Srivastava, and Yang G-Y (2011). Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KRasG12D/Pdx-Cre mice. August 22, Advance Access. Carcinogenesis, 32, 1689-1696.
19. S.Q. Hussaini, S. Wang, T. Salihima, Sanjay K. Srivastava and X. Liu (2011). Nanoemulsions of cancer chemopreventive agent benzyl isothiocyanate display enhanced solubility, dissolution and permeability. J. Agri. Food Chem. 59, 12396-12404.
20. S. Batra, R. Sahu, P.K. Kandala and Sanjay K. Srivastava (2010). Benzyl isothiocyanate mediated histone deacetylase inhibition leads to turn-off of NF-kB in human pancreatic cancer cells. Molecular Cancer Therapeutics, 9, 1596-1608.
21. P. Kandala and Sanjay K. Srivastava (2010). Activation of Chk2 by DIM is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Molecular Pharmacology, 78, 297-309.
22. R.P. Sahu and Sanjay K. Srivastava (2009). The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. Journal of National Cancer Institute. 101, 176-193.
23. R. Sahu, R. Zhang, S. Batra, Y. Shi and Sanjay K. Srivastava (2009). Benzyl isothiocyanate mediated generation of ROS causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis, 30, 1744-1753.
24. Sanjay K. Srivastava and R. Sahu (2009). Correspondence Re: The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. J. Natl. Can. Inst. 101 (12), 893-894.
25. R.P. Sahu, S. Batra, and Sanjay K. Srivastava (2009). Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. British. J. Cancer 100, 1425-1433.
26. R.P. Sahu, Michael W. Epperly and Sanjay K. Srivastava (2009). Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Frontiers in Bioscience E1, 568-576.
27. C.A. Wicker, R.P. Sahu, K. Kulkarni-Datar, Sanjay K. Srivastava, T.L. Brown (2009). BITC sensitizes pancreatic adenocarcinomas to TRAIL-induced apoptosis. Cancer Growth & Metastasis, 2, 45-55.
28. P.S. Rao, A. Satelli, S. Zhang, Sanjay K. Srivastava, K.S. Srivenugopal and U.S. Rao (2009). RNF2 is the target for phosphorylation by the p38 MAPK and ERK signaling pathways. Proteomics 9, 2776-2787.
29. N.M. Vad, P.K. Kandala, Sanjay K. Srivastava, M.Y. Moridani (2009). Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chem Biol Interact. 183, 462-471.
30. R. Zhang, I. Humphreys, R. P. Sahu, Y. Shi, and Sanjay K. Srivastava (2008). In vitro and in vivo induction of apoptosis by capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis, 13, 1465-1478.
31. Y. Shi, R.P. Sahu and Sanjay K. Srivastava (2008). Triphala inhibits both in vitro and in vivo growth of pancreatic tumor cells by inducing apoptosis. BMC- Cancer, 8, 294.



RECENT BOOK CHAPTERS:

1. R. Sahu and Sanjay K. Srivastava (2009). Preventive and therapeutic effects of naturally occurring isothiocyanates in cancer. Chapter 19 in: Herbal Medicine: A Cancer Chemopreventive and Therapeutic Perspective. Ed: R. Arora, Published by JayPee Brothers Medical Publishers Pvt. Ltd. pp278-288.
2. R. Sahu and Sanjay K. Srivastava (2011). Cruciferous vegetables derived isothiocyanates and cancer prevention. Chapter in: Functional Foods, Nutraceuticals and Degenerative Disease Prevention. Ed: G. Paliyath, Wiley-Blackwell Publishing.
3. S.B. Boreddy, K.C. Pramanik and Sanjay K. Srivastava (2012). Molecular targets of benzyl isothiocyanate in pancreatic cancer. Chapter 11 in: Pancreatic Cancer: Molecular Mechanism and Targets” by Intech Publisher Inc. March 2012. ISBN 978-953-51-0410-0. pp193-212.


BOOKS:

1. Sanjay K. Srivastava, Editor: “Pancreatic Cancer: Molecular Mechanism and Targets” by Intech Publisher Inc. March 2012. ISBN 978-953-51-0410-0.
2. Sanjay K. Srivastava, Editor: “Pancreatic Cancer: Clinical Management” by Intech Publisher Inc. March 2012. ISBN 978-953-51-0394-3.
3. Sanjay K. Srivastava, Editor: “Role of Capsaicin in Oxidative Stress and Cancer” to be published in the series “Diet and Cancer” by Springer Life Sciences Inc. Expected publication: 2012.


ABSTRACTS: More than 90 published abstracts.

EDITORIAL BOARD MEMBER:

• Journal of Nutritional Disorders and Therapy
• Journal of Cancer Science and Therapy
• Journal of Cell Death
• Cancer Growth and Metastasis
• World Journal of Gastrointestinal Oncology
• Journal of Cancer Therapy
• Drug Discoveries and Therapeutics
• Frontiers in Bioscience

AWARDS/HONORS:

• President’s Excellence in Research Award, 2010
• Graduate Teacher of the Year Award, 2010
• Citation Laureate Award, 2009

SOCIETY MEMBERSHIP:

1993 - present American Association for Cancer Research.
2007 - present Society of Toxicology
2007 - present American Association for Pharmaceutical Sciences
2007 - present American Association of College of Pharmacy

TEACHING COURSES:

PHAR 1401: Pharmacotherapy of Nonprescription Medicines
PHAR 3255: Gastroenterology and Hepatology
PHAR 3361: Case Studies I
GPSC 7101: Pharmaceutical Seminar
GPSC 5325: Cancer Biology and Therapeutics